[Latin Name] Allium sativum L.

[Plant Source] from China

[Appearance] Off-white to light yellow Powder

Plant Part Used:Fruit

[Particle size] 80 Mesh

[Loss on drying] ≤5.0%

[Heavy Metal] ≤10PPM

[Storage] Store in cool & dry area, keep away from the direct light and heat.

[Shelf life] 24 Months

[Package] Packed in paper-drums and two plastic-bags inside.

[Net weight] 25kgs/drum

Introduction:

In ancient times, garlic was used as a remedy for intestinal disorders, flatulence, worms, respiratory infections, skin diseases, wounds, symptoms of aging, and many other ailments. To date, more than 3000 publications from all over the world have gradually confirmed the traditionally recognized health benefits of garlic.

Although aged Garlic has so many benefits to human body, but it has a unpleasant odor. most of people do not like this taste ,so we use modern biological technology, to enrichment the elite containing in the Garlic and get rid of the odor of the product ,we call it aged garlic extract

Function:

(1) Has a strong and extensive antibiotic ability. It can kill all kinds of bacteria totally sucn as gram-positive bacteria, gram-negative bacteria and fungi; can restrain and kill some pathogenic microorganisms such as many staphylococcocci, pasteurella, typhoid bacillus, shigella dysenteriae and pseudomonas aeruginosa. So, it can prevent and cure many kinds of contagion, especially coccidiosis in chicken.

(2) Because of its strong garlic odour, allicin can increase feed intake of the birds and fish.

(3) Flavors the meals with a uniform garlic smell and mask unpleasant odors of various feed components.

(4) Strengthen immune system, and promote healthy growth in poultry and fish.

(5) Allicin’s garlic odour is effective in repelling flies, mites and other insects from the feed.

(6) Allicin has a potent sterilization effect on Aspergillus flavus, Aspergillus Niger, Aspergillus fumigatus, etc. and is therefore able to prevent the onset of feed mildew and prolong feed life.

(7) Allicin is safe with no residual drugs

This video shows you how to pronounce Luteolin

Title: Pneumococcal infections and vaccination.
4th International Conference on Vaccines & Vaccination
September 24-26, 2014 Valencia, Spain

OMICS International: https://omicsonline.org
Vaccine Conferences: https://conferenceseries.com/immunolog…
Global Medical Conferences: https://conferenceseries.com
Global Pharmaceutical Conferences: https://pharmaceuticalconferences.com
Global Cancer Conferences: https://cancersummit.org
Global Diabetes Conferences: https://diabetesexpo.com
Global Dental Conferences: https://dentalcongress.com
Global Nursing Conferences: https://nursingconference.com

Abstract
Pneumococci are major contributors to morbidity and mortality worldwide. They are the major cause of milder respiratory tract infections such as otitis and sinusitis, but also to more severe invasive infections such as community-acquired pneumonia with associated septicemia and meningitis. Even though being a devastating pathogen, pneumococci are also common colonizers of the upper respiratory tract of healthy children where from they may spread to cause disease. Risk groups for acquiring an invasive pneumococcal infection (IPD) include preschool children and the elderly, as well as immunocompromised individuals, splenectomised, and patients with a previous influenza virus infection. Several bacterial virulence factors have been described for pneumococci of which a major one is the capsular polysaccharide. Depending on differences in these capsular structures so far more than 90 different serotypes have been distinguished. Recently so called conjugated vaccines (PCV) have been introduced into the child hood vaccination program in many countries. These vaccines are based on a limited amount (7, 10 or 13) of the capsular serotypes. In Sweden PCVs were introduced in the whole of Sweden year 2009. Vaccine introduction has led to a reduction in the incidence of IPD in vaccinated children but also to serotype replacementand an increase of non-vaccine type disease.

Biography

Birgitta Henriques Normark is professor and head physician in Clinical microbiology at Karolinska Institute and Karolinska University hospital, as well as head physician at the Public Health Agency of Sweden. She is also vice dean for recruitment at Karolinska Institutet and a board member of the Swedish Research Council, Medicine and Health.Her research focuses on epidemiology, antibiotic resistance and host-microbe interactions in bacterial infections with special focus on pneumococcal epidemicity, molecular epidemiology, and mechanisms of invasive disease, innate immunity and host-microbe interactions determining disease outcome. The research has been published in 136 publications of which 107 are original peer reviewed articles.